DIAGNOS Enters the Retinal Diagnostics Market With its New

BROSSARD, Quebec, Oct. 27, 2022 (GLOBE NEWSWIRE) — DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) a pacesetter in early detection of essential well being points by the use of its FLAIRE platform based mostly on Artificial Intelligence (AI), is proud to announce it’s coming into the fast-growing retinal diagnostics market, armed with its new 3D picture evaluation know-how.

DIAGNOS is pushing the boundaries of the apply with a deep learning-powered know-how able to diagnosing retinal circumstances similar to Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma, Macular Edema, Retinal Cancer, and different retinal and macular ailments. Moreover, neurological and systemic ailments affecting different elements of the physique may also be recognized, together with Alzheimer’s illness, cardiovascular ailments, a number of sclerosis, Parkinson’s illness, and so forth.

The multimodal knowledge evaluation instruments developed by DIAGNOS benefit from the most up-to-date developments in ophthalmic science. Combining knowledge fetched from retinal photographs and optical coherence tomography (OCT) scans, DIAGNOS makes use of the most correct applied sciences that exist for retinal diagnostics. The know-how is extra exact than MRI and ultrasound scanning, it’s non-invasive, and integrates the evaluation of 3D cross-sectional photographs of the retina”.

“The growing interest for advanced retinal imaging systems by the healthcare sector, the adoption of healthcare reimbursement policies in multiple regions, and the evolution of the regulatory environment are some of the factors that made us take the decision to enter the retinal diagnostics market”, said Mr. Andre Larente, President of DIAGNOS. “Two of our main competitors have recently received investments of respectively $50M and $26M following their decision to enter the retinal diagnostics market, it certainly tells a lot about the potential of this category”.

Technological developments in diagnostic strategies, quickly altering healthcare infrastructure, rising adoption of superior retinal imaging techniques, and favorable healthcare reimbursement insurance policies contribute to the speedy development of this class, as it’s anticipated to develop into the gold commonplace of the future in the profitable administration of retinal problems.

About DIAGNOS
DIAGNOS is a publicly traded Canadian company devoted to early detection of essential well being issues based mostly on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE permits for fast modifying and creating of functions similar to CARA (Computer Assisted Retina Analysis). CARA’s picture enhancement algorithms present sharper, clearer and easier-to-analyze retinal photographs. CARA is a cheap device for real-time screening of enormous volumes of sufferers. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

Additional info is on the market at www.DIAGNOS.com and www.sedar.com

For additional info, please contact:

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450 678-8882, ext. 224
Email: [email protected]

This information launch accommodates forward-looking info. There will be no assurance that forward-looking info will show to be correct, as precise outcomes and future occasions might differ materially from these anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly replace or revise any forward-looking info, whether or not on account of new info, future occasions or in any other case. The forward-looking info contained on this information launch is expressly certified by this cautionary assertion.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that time period is outlined in the insurance policies of the TSX Venture Exchange) accepts duty for the adequacy or accuracy of this launch.

A photograph accompanying this announcement is on the market at https://www.globenewswire.com/NewsRoom/AttachmentNg/d943a458-d0b6-43db-8cc4-39482d7f9b85